KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) R&D In Process (2016 - 2026)

AbbVie has reported R&D In Process over the past 14 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly R&D In Process fell 9.64% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, up 97.68% year-over-year, with the annual reading at $5.0 billion for FY2025, 81.94% up from the prior year.
  • R&D In Process was $1.3 billion for Q4 2025 at AbbVie, down from $1.9 billion in the prior quarter.
  • Over five years, R&D In Process peaked at $1.9 billion in Q3 2025 and troughed at $40.0 million in Q3 2022.
  • The 5-year median for R&D In Process is $249.0 million (2024), against an average of $409.5 million.
  • Year-over-year, R&D In Process plummeted 90.0% in 2022 and then soared 2217.07% in 2025.
  • A 5-year view of R&D In Process shows it stood at $370.0 million in 2021, then crashed by 34.32% to $243.0 million in 2022, then grew by 16.05% to $282.0 million in 2023, then skyrocketed by 396.45% to $1.4 billion in 2024, then dropped by 9.64% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's R&D In Process are $1.3 billion (Q4 2025), $1.9 billion (Q3 2025), and $335.0 million (Q2 2025).